Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
Recent application of immunotherapy in clinical oncology revolutionized our management of advanced human cancers.Check point inhibitors targeting CTLA4 and PD-1/PD-L1 axis are immunotherapeutic agents currently available to treat a variety of cancers.However, a novel therapeutic approach is needed to further improve patient outcome with these agent